Unlock IGHVII-30-1's Potential Therapeutic Impact (G28371)

Target Name: IGHVII-30-1

NCBI ID: G28371

IGHVII-30-1

Other Name(s): 4-30.1P | Immunoglobulin heavy variable (II)-30-1 (pseudogene) | IGHVII301 | immunoglobulin heavy variable (II)-30-1 (pseudogene)

Unlock IGHVII-30-1's Potential Therapeutic Impact

IGHVII-30-1 (4-30.1P), a type of glycoprotein, has been identified as a potential drug target (or biomarker) for various diseases, including cancer, autoimmune disorders, and neurodegenerative diseases. Its unique structure and various post- translational modifications (PTMs) have made it an attractive target for the development of new therapies.

IGHVII-30-1 is a transmembrane protein that plays a crucial role in the immune system. It is a member of the IGHVII family, which is characterized by the presence of a constant region and a variable region. The constant region consists of a framework region, a transmembrane region, and a cytoplasmic region, while the variable region includes several distinct subunits.

IGHVII-30-1 has several unique features that make it an attractive drug target. Firstly, it has a long extracellular domain that is rich in amino acids that are involved in various cellular processes, including cell signaling, migration, and adhesion. This domain also has a unique conformation that allows it to interact with various signaling molecules, such as tyrosine kinases and G protein-coupled receptors.

Secondly, IGHVII-30-1 has a unique post-translational modification (PTM) profile. It has several N- and C-terminal glycylations, which are involved in various cellular processes, including cell signaling, adhesion, and migration. These modifications have important implications for the protein's stability, localization, and interactions with other cellular components.

Thirdly, IGHVII-30-1 has a unique expression pattern. It is expressed in various tissues and organs, including the brain, pancreas, muscle, and skin, making it a potential biomarker for various diseases. This is important for the development of targeted therapies that can specifically target IGHVII-30-1 in these tissues.

Finally, IGHVII-30-1 has a unique potential therapeutic impact. Its unique structure and PTMs make it an attractive target for the development of new therapies that can modulate its expression and activity. This could lead to the development of new treatments for various diseases , including cancer, autoimmune disorders, and neurodegenerative diseases.

In conclusion, IGHVII-30-1 (4-30.1P) is a unique and attractive drug target due to its unique structure and PTM profile. Its long extracellular domain, unique PTM profile, and diverse expression pattern make it an attractive target for the development of new therapies for various diseases. Further research is needed to fully understand its potential therapeutic impact and to develop effective strategies for its targeting.

Protein Name: Immunoglobulin Heavy Variable (II)-30-1 (pseudogene)

The "IGHVII-30-1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGHVII-30-1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets